Pharmaceuticals

The FDA has opened the first FY2027 funding cycle for its Minor Use and Minor Species (MUMS) animal drug grant program, offering up to $750,000 per project to support development of treatments for uncommon diseases and underserved animal species.

VMD Sciences announced expanded efforts to support large animal veterinarians facing ongoing pharmaceutical shortages and emerging infectious disease challenges, including limited availability of equine colic therapies and the spread of Theileriosis linked to the Asian longhorned tick.

The FDA has expanded emergency use authorization for Dectomax/Dectomax-CA1, building on the agency’s September 2025 conditional approval for New World screwworm treatment in cattle by adding dairy cattle, horses, swine, sheep, and deer to the authorized species list as of May 19, 2026.

The FDA has approved the first generic moxidectin oral drench for sheep, expanding treatment options for internal parasite control in a minor species.

Elanco has received FDA and EPA emergency authorizations for two products to help prevent and treat New World screwworm infestations, as the parasite approaches the U.S. border.

One year after launching its roadmap, the FDA says it has met key milestones in shifting drug development away from animal testing toward human-relevant scientific methods.

Vetirus Pharmaceuticals has partnered with Immune Propulsion to develop IPVM-173, a novel IgG-degrading protease aimed at enhancing anti-tumor immune responses in cats and dogs with large mass tumors.

Elanco has introduced the Advantage Collar for Dogs, an over‑the‑counter parasite control product designed to provide four months of continuous protection against fleas, ticks and mosquitoes.